Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study
Leonard H. van den Berg, Jeffrey D. Rothstein, Pamela J. Shaw, Suma Babu, Michael Benatar, Robert C. Bucelli, Angela Genge, Jonathan D. Glass, Orla Hardiman, Vincenzo Libri, Theodore Mobach, Björn Oskarsson, Gary L. Pattee, John Ravits, Christopher E. Shaw, Markus Weber, Lorne Zinman, Paymaan Jafar-nejad, Frank Rigo, Luan LinToby A. Ferguson, Anthony L. Gotter, Danielle Graham, Michael Monine, Jennifer Inra, Susie Sinks, Satish Eraly, Steve Garafalo, Stephanie Fradette
Dive into the research topics of 'Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study'. Together they form a unique fingerprint.